These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33850749)

  • 1. Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).
    Iwamura H; Hatakeyama S; Momota M; Kojima Y; Narita T; Okamoto T; Fujita N; Hamano I; Togashi K; Hamaya T; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
    Transl Androl Urol; 2021 Mar; 10(3):1143-1151. PubMed ID: 33850749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
    Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
    Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.
    Qiu J; Zhang H; Xu D; Li L; Xu L; Jiang Y; Wen T; Lu S; Meng F; Feng L; Shu X
    J Oncol; 2022; 2022():7306198. PubMed ID: 35607328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
    Kumar A; Cherry DR; Courtney PT; Nalawade V; Kotha N; Riviere PJ; Efstathiou J; McKay RR; Karim Kader A; Rose BS; Stewart TF
    Eur Urol Open Sci; 2021 Aug; 30():1-10. PubMed ID: 34337540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    Su X; Dong C; Liao W; Liu W
    World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
    Kim YJ; Byun SJ; Ahn H; Kim CS; Hong BS; Yoo S; Lee JL; Kim YS
    Oncotarget; 2017 Sep; 8(40):68996-69004. PubMed ID: 28978174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort.
    Finati M; Stephens A; Chiarelli G; Cirulli GO; Tinsley S; Wang Y; Sood A; Buffi N; Lughezzani G; Salonia A; Briganti A; Montorsi F; Busetto GM; Carrieri G; Rogers C; Abdollah F
    Urol Oncol; 2025 Jan; 43(1):61.e1-61.e9. PubMed ID: 39242301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
    Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis.
    Ding H; Fan N; Ning Z; Ma D
    Front Oncol; 2020; 10():564779. PubMed ID: 33154943
    [No Abstract]   [Full Text] [Related]  

  • 14. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model.
    Magee D; Cheung D; Hird A; Sridhar SS; Catton C; Chung P; Berlin A; Warde P; Zlotta A; Fleshner N; Kulkarni GS
    Can Urol Assoc J; 2022 Apr; 16(4):E197-E204. PubMed ID: 34812723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience.
    Fallatah M; Alkahtani AS; Alrumayyan M; Alotaibi MF; Alkhateeb S; Mokhtar AA; Altaweel W
    Urol Ann; 2023; 15(4):406-411. PubMed ID: 38074180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
    Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis.
    Al-Qudimat AR; Singh K; Ojha LK; Moustafa DA; Elaarag M; Al-Zoubi RM; Aboumarzouk OM
    Front Surg; 2023; 10():1276746. PubMed ID: 38130884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer.
    Okita K; Hatakeyama S; Momota M; Soma O; Hamano I; Tanaka T; Iwamura H; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Ohyama C
    Int J Urol; 2020 Aug; 27(8):649-654. PubMed ID: 32452113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review.
    Fukushima H; Koga F
    Transl Androl Urol; 2022 Oct; 11(10):1433-1441. PubMed ID: 36386266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.